VHT is trading 3% down in pre-market action following news that Sandoz has filed U.S. FDA applications for generic tirzepatide versions of Eli Lilly’s blockbuster drugs, Mounjaro and Zepbound.
- The move by Sandoz signals intensifying future competition in the high-growth diabetes and obesity markets, which have been primary drivers for major healthcare holdings.
- Analysts are raising concerns regarding long-term margin compression and growth sustainability for major GLP-1 manufacturers, weighing on the broader healthcare sector.
- The downward pressure on the ETF comes despite relatively flat index futures, reflecting sector-specific anxiety over the generic filing.